| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Feb, 2026 |
| Sales | 0 | 60 | 0 | 0 | 0 |
| Sales Growth | -100.00% | unch | unch | unch | unch |
| Net Income | -88,080 | -70,890 | -32,480 | -20,420 | 0 |
| Net Income Growth | -24.25% | -118.26% | -59.06% | unch | unch |
Gracell Biotechnologies Inc ADR
(GRCL)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company. It involved in discovering and developing breakthrough cell therapies to address unmet medical needs in the treatment of cancer. Gracell Biotechnologies Inc. is based in SUZHOU, China.
Fiscal Year End Date: 12/31